 |
|
|
| |
A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naïve Genotype 1 HCV-Infected Subjects
|
| |
| |
Reported by Jules Levin
AASLD October 29-November 2, 2010 Boston, Massachusetts
J. Lalezari1, W. O'Riordan2, F. Poordad3, T. Nguyen4, G. Dubuc Patrick5, J. Chen5, X.J. Zhou5, J. Z. Sullivan-Bólyai5, D. Mayers5 and the IDX-08C-004 Investigator Group
1Quest Clinical Research, San Francisco, CA; 2e Study Site, San Diego, CA; 3Cedars-Sinai Medical Center, Los Angeles, CA; 4San Diego, CA; 5Idenix Pharmaceuticals, Inc., Cambridge, MA
|
| |
|
|
|
|
|
